---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-094884"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:11:55.129045+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics appoints Joseph Talamo as CFO; John Wesolowski returns to Controller role

## Summary
- Joseph Talamo appointed CFO effective Dec 11, 2023; replaces interim CFO John Wesolowski.
- Talamo brings 25+ years biopharma experience; previously CFO of HiberCell and Caladrius Biosciences.
- Compensation: $370k base salary, 35% target bonus, 80,000 options at $6.88 exercise price (4-year vest).
- Wesolowski remains as Principal Accounting Officer and Controller.

## SEC filing metadata
- accession: 0001213900-23-094884
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000121390023094884/0001213900-23-094884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000121390023094884/ea189864-8k_intensity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-094884
- JSON: https://secwatch.observer/filing/0001213900-23-094884.json
- Plain text: https://secwatch.observer/filing/0001213900-23-094884.txt

## Key facts
- Executive change
  John Wesolowski changed role as Chief Financial Officer at INTENSITY THERAPEUTICS, INC..
  - Action: ceased serving as interim
  - Role: Chief Financial Officer
  source text: With the appointment of Mr. Talamo as the Company’s new Chief Financial Officer, Mr. Wesolowski will no longer serve in this capacity but will continue on as the Company’s Principal Accounting Officer and Controller.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000121390023094884/0001213900-23-094884-index.htm
- Executive change
  Joseph Talamo was appointed as Chief Financial Officer at INTENSITY THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On December 11, 2023, Intensity Therapeutics (the “Company”), appointed Joseph Talamo to serve as the Chief Financial Officer of the Company effective December 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000121390023094884/0001213900-23-094884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.